Swissmedic has announced a recall of batch number 242867651 for the product GlucoSaline B. Braun Infusion Solution. This action affects retailers and highlights a significant development in pharmaceutical safety and oversight.
What changed?
Swissmedic, Switzerland’s medical regulatory authority, has officially called for a recall of batch 242867651 of GlucoSaline B. Braun Infusion Solution as of November 14, 2025. This action targets distribution points, including retail locations, to ensure that the specified batch is completely withdrawn.
The announcement signals concerns over a quality issue that requires immediate attention. Swissmedic has not disclosed detailed reasons for the recall in the provided notice, underscoring the importance of compliance with regulatory mandates.
Who is affected?
Clinical staff, pharmaceutical retailers, and quality assurance professionals should take note of this significant development. Retail businesses carrying this specific product batch are required to comply with the recall directive.
The recall may also impact patient care, where healthcare providers should verify stocks to ensure that the affected batch is removed from circulation. Communication channels between stakeholders, including distributors and healthcare institutions, are crucial in addressing safety concerns effectively.
FAQ
Q1: What product is affected?
A1: The recall concerns GlucoSaline B. Braun Infusion Solution, specifically batch number 242867651.
Q2: What stage of the distribution chain is targeted?
A2: The recall is directed at retail distribution points, and compliance is expected at this level.
Q3: Is patient safety directly impacted?
A3: While no specific patient risk details are provided in the Swissmedic notice, healthcare providers are advised to ensure the affected batch is no longer in use.
Conclusion
The recall of GlucoSaline B. Braun Infusion Solution batch 242867651 serves as a reminder of the importance of maintaining rigorous quality standards in healthcare products. Clinical, quality, and regulatory teams should act promptly to comply with Swissmedic’s directive and safeguard patient health.
Disclaimer
This article is intended to inform healthcare and regulatory professionals of the recent recall. It does not constitute legal or medical advice. For precise guidance, consult Swissmedic directly.
Swissmedic Announcement
For full information about the Swissmedic announcement, see the link below.